Residual effects and skills related to driving after a single oral administration of diazepam, medazepam or lorazepam

British Journal of Clinical Pharmacology
K SeppäläM Linnoila

Abstract

Psychomotor skills and visual functions related to driving were measured double-blind cross-over in ten healthy volunteers before, and 1,3,5 and 7 h after a single oral administration of diazepam (10mg), medazepam (15 mg) or lorazepam (2.5 mg). The late effects of lorazepam were tested in seven other subjects 12 and 24 h after the administration. Lorazepam impaired almost all the measured skills more (P less than 0.05 to 0.001) than diazepam, medizepam or the placebo. The lorazepam impairment of reactive skills and flicker fusion discrimination remained statistically significant (P less than 0.05) for as long as 12 h. Medazepam impaired only reactive skills and flicker fusion, the latter remaining impaired (P less than 0.05) for as long a 5 h after the administration. The magnitude and duration of the effects of diazepam were intermediate between those of lorazepam and medazepam. Diazepam impaired perceptual speed and reactive and co-ordinative skills as well as flicker fusion discrimination and visual parameters related to driving. Slight impairments in performance were measurable for up to 5 h after administration but at 7 h the results resembled those measured after the placebo. The lack of alterations in adaptation to dark...Continue Reading

References

Jan 1, 1976·Acta Anaesthesiologica Scandinavica·K Korttila, M Linnoila
Jul 23, 1975·Psychopharmacologia·A PenttiläJ Lönnqvist
Jan 1, 1973·The Journal of Pharmacy and Pharmacology·R W BellP Turner
Dec 21, 1974·British Medical Journal·D I Jeffery, M F Whitfield
Jan 1, 1973·Current Medical Research and Opinion·A B KhoranaA S Nanivadekar
Jan 1, 1973·Current Medical Research and Opinion·D EavesR P Swinson
Jan 1, 1973·Current Medical Research and Opinion·J T Silverstone
Apr 1, 1974·Clinical Pharmacology and Therapeutics·M Linnoila, S Häkkinen
Aug 23, 1974·European Journal of Clinical Pharmacology·M LinnoilaM Maki
Dec 1, 1974·British Journal of Anaesthesia·K Korttila, M Linnoila
Mar 1, 1974·Annals of Internal Medicine·L E Hollister
Jan 16, 1971·British Medical Journal·R J Kerry, C M McDermott
May 1, 1971·Clinical Pharmacology and Therapeutics·H W ElliottW H Comer
Dec 1, 1971·The British Journal of Psychiatry : the Journal of Mental Science·I Haider
Oct 1, 1971·British Journal of Industrial Medicine·H Hänninen
Feb 1, 1971·British Journal of Anaesthesia·I G Grove-White, G R Kelman
Dec 1, 1974·British Journal of Clinical Pharmacology·T Silverstone

Citations

Oct 1, 1978·British Journal of Clinical Pharmacology·C H Clarke, A N Nicholson
Jan 1, 1979·British Journal of Clinical Pharmacology·A N Nicholson
May 11, 1985·British Medical Journal·J Catalan, D Gath
Apr 1, 1996·Environmental Health Perspectives·A Wetherell
Sep 29, 2007·Anesthesia Progress·Mark DonaldsonBrian Chanpong
Mar 7, 2003·Canadian Journal of Anaesthesia = Journal Canadien D'anesthésie·David R SinclairAlison Smiley
Jan 1, 1983·Progress in Neuro-psychopharmacology & Biological Psychiatry·S G McKenzie
Jan 1, 1987·European Journal of Clinical Pharmacology·A PatatM Hucher
Jan 1, 1988·European Journal of Clinical Pharmacology·A PatatJ Granier
Jan 1, 1992·European Journal of Clinical Pharmacology·A Irving, W Jones
Jan 1, 1990·Acta Anaesthesiologica Scandinavica·K KorttilaL J Fischer
Jan 1, 1978·Acta Anaesthesiologica Scandinavica·K Korttila, T Seppälä
Jan 1, 1979·British Journal of Clinical Pharmacology·A N Nicholson
May 7, 2011·Drug and Alcohol Review·Stefanie Y Leung
May 1, 1983·British Journal of Clinical Pharmacology·K ArankoT Seppälä
Dec 1, 1982·Acta Anaesthesiologica Scandinavica·J Kanto, U Klotz
Aug 1, 1980·British Journal of Clinical Pharmacology·I Hindmarch, A C Gudgeon
Sep 1, 1980·British Journal of Clinical Pharmacology·I Hindmarch
Aug 1, 1986·Anaesthesia·V Narang, J R Laycock
Jul 28, 2004·Traffic Injury Prevention·E J D Ogden, H Moskowitz
Mar 1, 1988·The British Journal of Psychiatry : the Journal of Mental Science·J CatalanJ Ennis
Jun 18, 2019·Journal of Clinical Psychopharmacology·Richard I Shader
Feb 18, 1999·The American Journal of Gastroenterology·M OkamotoM A Fujino
Jun 1, 1984·The British Journal of Psychiatry : the Journal of Mental Science·J CatalanP Martin
May 1, 1979·Acta Pharmacologica Et Toxicologica·R Liljequist, M J Mattila
Jan 1, 1983·Acta Pharmacologica Et Toxicologica·T Seppälä, R Visakorpi
Jul 1, 1980·Acta Pharmacologica Et Toxicologica·M LinnoilaP Routledge
May 1, 1982·Acta Pharmacologica Et Toxicologica·E S PalvaT Seppälä
Jul 1, 1985·British Journal of Clinical Pharmacology·A Patat, P Foulhoux
Feb 1, 1978·Journal of Clinical Pharmacology·S NakanoE Osato
Apr 1, 1990·Journal of Pharmacokinetics and Biopharmaceutics·S K GuptaD G Heatherly
Jan 1, 1981·British Journal of Clinical Pharmacology·A N Nicholson
Jun 13, 1981·The Medical Journal of Australia·A A Landauer

Related Concepts

Automobile Driving
Dark Adaptation
Valium
Flicker Fusion
Sedicepan
Medazepam AWD
Motor Skills
Placebos
Reaction Time
Anti-Anxiety Effect

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Systemic Juvenile Idiopathic Arthritis

Systemic juvenile idiopathic arthritis is a rare rheumatic disease that affects children. Symptoms include joint pain, but also fevers and skin rashes. Here is the latest on this disease.

Chromatin Regulation and Circadian Clocks

The circadian clock plays an important role in regulating transcriptional dynamics through changes in chromatin folding and remodelling. Discover the latest research on Chromatin Regulation and Circadian Clocks here.

Central Pontine Myelinolysis

Central Pontine Myelinolysis is a neurologic disorder caused most frequently by rapid correction of hyponatremia and is characterized by demyelination that affects the central portion of the base of the pons. Here is the latest research on this disease.

Myocardial Stunning

Myocardial stunning is a mechanical dysfunction that persists after reperfusion of previously ischemic tissue in the absence of irreversible damage including myocardial necrosis. Here is the latest research.

Pontocerebellar Hypoplasia

Pontocerebellar hypoplasias are a group of neurodegenerative autosomal recessive disorders with prenatal onset, atrophy or hypoplasia of the cerebellum, hypoplasia of the ventral pons, microcephaly, variable neocortical atrophy and severe mental and motor impairments. Here is the latest research on pontocerebellar hypoplasia.

Cell Atlas Along the Gut-Brain Axis

Profiling cells along the gut-brain axis at the single cell level will provide unique information for each cell type, a three-dimensional map of how cell types work together to form tissues, and insights into how changes in the map underlie health and disease of the GI system and its crosstalk with the brain. Disocver the latest research on single cell analysis of the gut-brain axis here.

Chronic Traumatic Encephalopathy

Chronic Traumatic Encephalopathy (CTE) is a progressive degenerative disease that occurs in individuals that suffer repetitive brain trauma. Discover the latest research on traumatic encephalopathy here.